Ipsen Biopharmaceuticals, Inc. et al. v. Conjupro Biotherapeutics, Inc. et al.
consolidated; administratively terminated as standalone docket; pending in consolidated action- Docket:
- 1:25-cv-13647
- Filed:
- 2025-07-22
- Terminated:
- 2025-09-05
Patents:12364691
π Ipsen Biopharmaceuticals, Inc.π Ipsen Biopharm Ltd.Δ Conjupro Biotherapeutics, Inc.Δ CSPC Pharmaceutical Group LimitedΔ CSPC Ouyi Pharmaceutical Co., Ltd.
Ipsen sued Conjupro and CSPC defendants in the District of New Jersey for infringement of U.S. Patent No. 12,364,691 under 35 U.S.C. § 271 based on Conjupro's proposed irinotecan liposome injection (generic Onivyde), NDA No. 218923. The case was consolidated with Docket No. 24-4991, and the 25-13647 docket was administratively terminated on September 5, 2025; the '691 claims proceed in the consolidated action.